KR20060031803A - 생물방어를 위한 면역치료제 - Google Patents

생물방어를 위한 면역치료제 Download PDF

Info

Publication number
KR20060031803A
KR20060031803A KR1020057023203A KR20057023203A KR20060031803A KR 20060031803 A KR20060031803 A KR 20060031803A KR 1020057023203 A KR1020057023203 A KR 1020057023203A KR 20057023203 A KR20057023203 A KR 20057023203A KR 20060031803 A KR20060031803 A KR 20060031803A
Authority
KR
South Korea
Prior art keywords
ser
gly
ala
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057023203A
Other languages
English (en)
Korean (ko)
Inventor
캐서린 에스. 보우디쉬
샤나 프레데릭손
마르타 에이. 와일드
도시아끼 마루야마
메리 진 놀란
Original Assignee
알렉시온 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉시온 파마슈티칼스, 인코포레이티드 filed Critical 알렉시온 파마슈티칼스, 인코포레이티드
Publication of KR20060031803A publication Critical patent/KR20060031803A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057023203A 2003-06-02 2004-05-26 생물방어를 위한 면역치료제 Withdrawn KR20060031803A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/452,593 2003-06-02
US10/452,593 US20040258699A1 (en) 2002-02-11 2003-06-02 Immunotherapeutics for biodefense

Publications (1)

Publication Number Publication Date
KR20060031803A true KR20060031803A (ko) 2006-04-13

Family

ID=33551270

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057023203A Withdrawn KR20060031803A (ko) 2003-06-02 2004-05-26 생물방어를 위한 면역치료제

Country Status (9)

Country Link
US (1) US20040258699A1 (https=)
EP (1) EP1648487A2 (https=)
JP (1) JP2006526639A (https=)
KR (1) KR20060031803A (https=)
CN (1) CN1829525A (https=)
AU (1) AU2004247034A1 (https=)
CA (1) CA2527843A1 (https=)
IL (1) IL172231A0 (https=)
WO (1) WO2004110362A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046228A2 (en) * 2000-12-05 2002-06-13 Wisconsin Alumni Research Foundation Receptor for b. anthracis toxin
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
WO2005007804A2 (en) * 2003-04-10 2005-01-27 President And Fellows Of Harvard College Anthrax conjugate vaccine and antibodies
ES2376337T3 (es) * 2004-03-03 2012-03-13 Iq Therapeutics Bv Anticuerpos monoclonales neutralizantes de la toxina del �?ntrax humanos y métodos para su uso.
CA2591665C (en) * 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
WO2008063147A2 (en) * 2005-03-31 2008-05-29 The General Hospital Corporation Anthrax polypeptide binding
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
US7794732B2 (en) 2006-05-12 2010-09-14 Oklahoma Medical Research Foundation Anthrax compositions and methods of use and production
CA2881717C (en) * 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
US8540987B2 (en) * 2008-01-29 2013-09-24 Institute For Antibodies Co., Ltd. Composition for neutralizing botulinus toxin type-A, and human anti-botulinus toxin type-A antibody
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB0812316D0 (en) * 2008-07-07 2008-08-13 Secr Defence Antibody
US8343495B2 (en) * 2009-01-10 2013-01-01 Auburn University Equine antibodies against Bacillus anthracis for passive immunization and treatment
CN103172734A (zh) * 2013-04-07 2013-06-26 中国人民解放军南京军区军事医学研究所 人源抗炭疽毒素保护性抗原中和抗体Fab及应用
TWI606834B (zh) * 2014-10-24 2017-12-01 國立陽明大學 缺氧培養之間葉幹細胞用於修復血管內皮細胞的應用
CN104628853B (zh) * 2015-02-06 2017-10-10 中国人民解放军南京军区军事医学研究所 人源抗炭疽保护性抗原PA的抗体IgG及其应用
US11013815B2 (en) 2017-06-14 2021-05-25 Monojul, Llc High-affinity anti-human folate receptor beta antibodies and methods of use
CN109081869B (zh) 2018-08-28 2022-06-03 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白
CN109134647B (zh) 2018-08-28 2020-08-04 东莞市朋志生物科技有限公司 Ns1蛋白的结合蛋白
WO2023003679A1 (en) * 2021-07-22 2023-01-26 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Single domain antibodies that bind and neutralize venezuelan equine encephalitis virus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278764A4 (en) * 2000-05-04 2004-05-19 Harvard College CONNECTIONS AND METHODS FOR TREATING AND PREVENTING BACTERIAL INFECTIONS (11/14/01)
US20040009178A1 (en) * 2002-02-11 2004-01-15 Bowdish Katherine S. Immunotherapeutics for biodefense

Also Published As

Publication number Publication date
EP1648487A2 (en) 2006-04-26
CN1829525A (zh) 2006-09-06
JP2006526639A (ja) 2006-11-24
US20040258699A1 (en) 2004-12-23
CA2527843A1 (en) 2004-12-23
AU2004247034A1 (en) 2004-12-23
WO2004110362A3 (en) 2005-07-28
IL172231A0 (en) 2006-04-10
WO2004110362A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
KR20060031803A (ko) 생물방어를 위한 면역치료제
US20040009178A1 (en) Immunotherapeutics for biodefense
CN111690059B (zh) 一种抗SARS-CoV-2的单克隆抗体1D7
CN111718411B (zh) 一种抗SARS-CoV-2的单克隆抗体1F2
CN116023478B (zh) 冠状病毒的中和抗体或其抗原结合片段
EP2414387B1 (en) Compositions and methods related to protein a (spa) variants
CN104892753B (zh) 一种中和人感染h7n9甲型流感病毒的抗体及其用途
CN115710311A (zh) 冠状病毒的抗体或其抗原结合片段
CN111333723B (zh) 针对狂犬病病毒g蛋白的单克隆抗体及其用途
WO2020038147A1 (zh) 抗bcma的单域抗体及其应用
JP2009518320A (ja) 抗オルトポックスウイルス組換えポリクローナル抗体
JP2012010714A (ja) ボツリヌス神経毒素を中和する治療的モノクローナル抗体
CN107022532A (zh) 涉及突变体难辨梭菌毒素的组合物及其方法
CA2607771A1 (en) Humanized anti-venezuelan equine encephalitis virus recombinant antibody
US20170158753A1 (en) Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species
US20240254202A1 (en) Llama-derived nanobodies binding the spike protein of novel coronavirus sars-cov-2 with neutralizing activity and application thereof
EP2464657B1 (en) Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
KR101958312B1 (ko) 보툴리눔 a형 독소에 대한 항체
CA2485120A1 (en) Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
CN104592385B (zh) 一种抗炭疽芽孢杆菌pa抗原的全人源抗体
CN113817051A (zh) 一种抗SARS-CoV-2的单克隆抗体1B6
US8501157B2 (en) Humanized anti-Venezuelan equine encephalitis virus recombinant antibodies
Kgagudi Delineating Antibody Responses Elicited by Four SARS-CoV-2 Variants against the Mu Variant
CN120865397A (zh) 一种c型肉毒毒素受体结合域纳米抗体及其应用
CN118290572A (zh) 抗狂犬病病毒全人源抗体及其组合物与应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20051202

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid